Regeneron's gene therapy study shows improved hearing in children with congenital deafness

New, positive data for Regeneron Pharmaceuticals' DB-OTO gene therapy among children with profound genetic hearing loss were presented at the Association for Research in Otolaryngology’s (ARO) 48th Annual MidWinter Meeting, according to a press release from the pharmaceutical company.